Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Association between coffee, tobacco, and alcohol daily consumption and sleep/wake cycle: an actigraphy study in euthymic patients with bipolar disorders.

Gross G, Maruani J, Vorspan F, Benard V, Benizri C, Brochard H, Geoffroy PA, Kahn JP, Yeim S, Leboyer M, Bellivier F, Etain B.

Chronobiol Int. 2020 Feb 12:1-11. doi: 10.1080/07420528.2020.1725542. [Epub ahead of print]

PMID:
32048536
2.

Childhood maltreatment and clinical severity of treatment-resistant depression in a French cohort of outpatients (FACE-DR): One-year follow-up.

Yrondi A, Aouizerate B, Bennabi D, Richieri R, D'Amato T, Bellivier F, Bougerol T, Horn M, Camus V, Courtet P, Doumy O, Genty JB, Holtzmann J, Lancon C, Leboyer M, Llorca PM, Maruani J, Moirand R, Molière F, Samalin L, Schmitt L, Stephan F, Turecki G, Vaiva G, Walter M, Petrucci J; FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) Collaborators, Haffen E, El-Hage W.

Depress Anxiety. 2020 Jan 30. doi: 10.1002/da.22997. [Epub ahead of print]

PMID:
31999402
3.

Eveningness and poor sleep quality contribute to depressive residual symptoms and behavioral inhibition in patients with bipolar disorder.

Caruso D, Meyrel M, Krane-Gartiser K, Benard V, Benizri C, Brochard H, Geoffroy PA, Gross G, Maruani J, Prunas C, Yeim S, Palagini L, Dell'Osso L, Leboyer M, Bellivier F, Etain B.

Chronobiol Int. 2020 Jan;37(1):101-110. doi: 10.1080/07420528.2019.1685533. Epub 2019 Nov 5.

PMID:
31690130
4.

Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression: Results From the FACE-DR Study.

Godin O, Bennabi D, Yrondi A, Richieri R, D'Amato T, Bellivier F, Bougerol T, Horn M, Camus V, Courtet P, Doumy O, Genty JB, El-Hage W, Haesebaert F, Holtzmann J, Lancon C, Leboyer M, Llorca PM, Maruani J, Molière F, Samalin L, Schmitt L, Stephan F, Vaiva G, Aouizerate MWB, Haffen E; FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) Collaborators.

J Clin Psychiatry. 2019 Oct 15;80(6). pii: 19m12755. doi: 10.4088/JCP.19m12755.

PMID:
31617968
5.

Does childhood experience of attention-deficit hyperactivity disorder symptoms increase sleep/wake cycle disturbances as measured with actigraphy in adult patients with bipolar disorder?

Prunas C, Krane-Gartiser K, Nevoret C, Benard V, Benizri C, Brochard H, Faedda G, Geoffroy PA, Gross G, Katsahian S, Maruani J, Yeim S, Leboyer M, Bellivier F, Scott J, Etain B.

Chronobiol Int. 2019 Aug;36(8):1124-1130. doi: 10.1080/07420528.2019.1619182. Epub 2019 Jun 6.

PMID:
31169034
6.

Bright Light as a Personalized Precision Treatment of Mood Disorders.

Maruani J, Geoffroy PA.

Front Psychiatry. 2019 Mar 1;10:85. doi: 10.3389/fpsyt.2019.00085. eCollection 2019. Review.

7.

Which actigraphic variables optimally characterize the sleep-wake cycle of individuals with bipolar disorders?

Krane-Gartiser K, Scott J, Nevoret C, Benard V, Benizri C, Brochard H, Geoffroy PA, Katsahian S, Maruani J, Yeim S, Leboyer M, Bellivier F, Etain B.

Acta Psychiatr Scand. 2019 Mar;139(3):269-279. doi: 10.1111/acps.13003.

PMID:
30689212
8.

Bright Light Therapy in the Morning or at Mid-Day in the Treatment of Non-Seasonal Bipolar Depressive Episodes (LuBi): Study Protocol for a Dose Research Phase I / II Trial.

Geoffroy PA, Abbassi EMBE, Maruani J, Etain B, Lejoyeux M, Amad A, Courtet P, Dubertret C, Gorwood P, Vaiva G, Bellivier F, Chevret S.

Psychiatry Investig. 2018 Dec;15(12):1188-1202. doi: 10.30773/pi.2018.09.27.1. Epub 2018 Nov 26.

9.

Clinical characteristics of obstructive sleep apnea in bipolar disorders.

Geoffroy PA, Micoulaud Franchi JA, Maruani J, Philip P, Boudebesse C, Benizri C, Yeim S, Benard V, Brochard H, Leboyer M, Bellivier F, Etain B.

J Affect Disord. 2019 Feb 15;245:1-7. doi: 10.1016/j.jad.2018.10.096. Epub 2018 Oct 9.

PMID:
30359809
10.

The neurobiology of adaptation to seasons: Relevance and correlations in bipolar disorders.

Maruani J, Anderson G, Etain B, Lejoyeux M, Bellivier F, Geoffroy PA.

Chronobiol Int. 2018 Sep;35(10):1335-1353. doi: 10.1080/07420528.2018.1487975. Epub 2018 Jun 25.

PMID:
29939763
11.

Metabolic syndrome and actigraphy measures of sleep and circadian rhythms in bipolar disorders during remission.

Brochard H, Godin O, Geoffroy PA, Yeim S, Boudebesse C, Benizri C, Benard V, Maruani J, Leboyer M, Bellivier F, Etain B.

Acta Psychiatr Scand. 2018 Aug;138(2):155-162. doi: 10.1111/acps.12910. Epub 2018 May 30.

PMID:
29845615
12.

Mifepristone and misoprostol for cervical ripening in surgical abortion between 12 and 14 weeks of gestation: a randomized controlled trial.

Ohannessian A, Baumstarck K, Maruani J, Cohen-Solal E, Auquier P, Agostini A.

Eur J Obstet Gynecol Reprod Biol. 2016 Jun;201:151-5. doi: 10.1016/j.ejogrb.2016.04.007. Epub 2016 Apr 11.

PMID:
27132200
13.

[Prophylactic antibiotics and intrauterine procedures].

Shojai R, Ohannessian A, Maruani J, Agostini A.

J Gynecol Obstet Biol Reprod (Paris). 2012 Dec;41(8):913-21. doi: 10.1016/j.jgyn.2012.09.021. Epub 2012 Nov 9. Review. French.

14.

A double-blind, randomized controlled trial of the use of a 50:50 mixture of nitrous oxide/oxygen in legal abortions.

Agostini A, Maruani J, Roblin P, Champion J, Cravello L, Gamerre M.

Contraception. 2012 Jul;86(1):79-83. doi: 10.1016/j.contraception.2011.11.015. Epub 2012 Jan 20.

PMID:
22264664
15.

Relaxation-time determination from continuous-microwave saturation of EPR spectra.

Lund A, Sagstuen E, Sanderud A, Maruani J.

Radiat Res. 2009 Dec;172(6):753-60. doi: 10.1667/RR1890.1.

PMID:
19929422
16.

Automatic fitting to 'powder' EPR spectra of coupled paramagnetic species employing Feynman's theorem.

Lund A, Gustafsson H, Maruani J, Shiotani M.

Spectrochim Acta A Mol Biomol Spectrosc. 2006 Mar 13;63(4):830-5. Epub 2006 Feb 3.

PMID:
16458575
17.

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G.

J Pharmacol Exp Ther. 2004 Sep;310(3):905-14. Epub 2004 May 6.

PMID:
15131245
18.

SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.

Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, Urban-Szabo K, Martinolle JP, Soubrié P, Finance O, Le Fur G.

J Pharmacol Exp Ther. 2004 May;309(2):661-9. Epub 2004 Jan 27.

PMID:
14747609
19.

Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice.

Poncelet M, Maruani J, Calassi R, Soubrié P.

Neurosci Lett. 2003 Jun 12;343(3):216-8.

PMID:
12770700
20.

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.

Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, Le Fur G.

Psychopharmacology (Berl). 1997 Jul;132(1):104-6.

PMID:
9272766
21.

Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A.

Pério A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrié P.

Behav Pharmacol. 1996 Jan;7(1):65-71.

PMID:
11224395
22.

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, et al.

FEBS Lett. 1994 Aug 22;350(2-3):240-4.

23.

Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors.

Jung M, Calassi R, Maruani J, Barnouin MC, Souilhac J, Poncelet M, Gueudet C, Emonds-Alt X, Soubrié P, Brelière JC, et al.

Neuropharmacology. 1994 Feb;33(2):167-79.

PMID:
8035902
24.

Anticonvulsant activity of 4,9-dioxo-5,10-diazatetradecane (CM 40142), a new GABA derivative, in mice and photosensitive baboons).

Chambon JP, Molimard JC, Calassi R, Maruani J, Rodier D, Sigault G, Leyris R, Roncucci R, Bizière K.

Arzneimittelforschung. 1984;34(9):1017-21.

PMID:
6439227

Supplemental Content

Loading ...
Support Center